91 related articles for article (PubMed ID: 16542209)
1. A study of codispensing with sodium alendronate in Australia.
Boyd IW; McEwen J; Calcino LJ
Br J Clin Pharmacol; 2006 Apr; 61(4):470-3. PubMed ID: 16542209
[TBL] [Abstract][Full Text] [Related]
2. Secondary prevention of osteoporosis in Australia: analysis of government-dispensed prescription data.
Hollingworth SA; Gunanti I; Nissen LM; Duncan EL
Drugs Aging; 2010 Mar; 27(3):255-64. PubMed ID: 20210370
[TBL] [Abstract][Full Text] [Related]
3. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
4. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
[TBL] [Abstract][Full Text] [Related]
5. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus.
Yeap SS; Fauzi AR; Kong NC; Halim AG; Soehardy Z; Rahimah I; Chow SK; Goh EM
J Rheumatol; 2008 Dec; 35(12):2344-7. PubMed ID: 19004038
[TBL] [Abstract][Full Text] [Related]
6. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway.
Devold HM; Furu K; Skurtveit S; Tverdal A; Falch JA; Sogaard AJ
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):297-304. PubMed ID: 22237942
[TBL] [Abstract][Full Text] [Related]
7. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
8. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
9. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
11. Prescription of alendronate and risedronate in men: off-label use in a health area.
León Vázquez F; Herrero Hernández S; Cuerpo Triguero C; Andrés Prado MJ; Cabello Ballesteros L
Reumatol Clin; 2015; 11(2):64-7. PubMed ID: 25107345
[TBL] [Abstract][Full Text] [Related]
12. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover.
Cohen A; Addesso V; McMahon DJ; Staron RB; Namerow P; Maybaum S; Mancini D; Shane E
Transplantation; 2006 Mar; 81(5):686-91. PubMed ID: 16534469
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
14. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
[TBL] [Abstract][Full Text] [Related]
15. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
[TBL] [Abstract][Full Text] [Related]
17. Alendronate is effective to treat bone loss in renal transplantation recipients.
Lan G; Peng L; Xie X; Peng F; Wang Y; Yu S
Transplant Proc; 2008 Dec; 40(10):3496-8. PubMed ID: 19100422
[TBL] [Abstract][Full Text] [Related]
18. The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis.
Landfeldt E; Ström O
Bone; 2012 Oct; 51(4):637-42. PubMed ID: 22842329
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
